AngioDynamics, Inc.

WHO'M
ai
Digital Profiler. Einfach den AI-Button klicken
CUSIP
03475V101
SEDOL
B00CR04
CIK
0001275187
www.angiodynamics.com
LEI:
©
FIGI: BBG000BB5621
ANGO
AngioDynamics, Inc.
GICS: - · Sektor: Healthcare · Sub-Sektor: Medical Instruments & Supplies
AI
PROFILER
NAME
AngioDynamics, Inc.
ISIN
US03475V1017
TICKER
ANGO
MIC
XNAS
REUTERS
ANGO.OQ
BLOOMBERG
ANGO US
BUILD THEMEFOLIO IDEEN TEILEN DISKUTIEREN
HEBEL INVESTIEREN
GIF DE 728x90
Financial Intelligence
360° iHub Crowd ATH Tracker Index Tracker ETF TF Spicy X-Billboard
FÜR INVESTOREN
FÜR TRADER
Börsenhandel Warrants
Der X-News Explorer ist die ultimative Informationsquelle für börsenaffine Anleger, die sich schnell und komfortabel einen Überblick über die aktuelle Nachrichtenlage eines börsennotierten Unternehmens verschaffen möchten. Ihnen stehen hier verschiedene Newswire-Services zur Verfügung. Wird ein News-Alert angezeigt, liegen Unternehmensnachrichten vor, die Sie möglicherweise interessieren könnten. Dieser Service wird Ihnen von BusinessWire bereitgestellt.
Mo., 06.01.2025       AngioDynamics
US03475V1017

AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive...
weiterlesen
AngioDynamics
Research & Analysen Termsheet Terminal
Permalink
Mo., 06.01.2025       AngioDynamics
US03475V1017

AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced that the Company will host a virtual investor event on Wednesday, January 8, 2025 at 9:30a...
weiterlesen
AngioDynamics
Research & Analysen Termsheet Terminal
Permalink
Do., 19.12.2024       AngioDynamics
US03475V1017

AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it will report financial results for the second quarter of fiscal year 2025 before the mark...
weiterlesen
AngioDynamics
Research & Analysen Termsheet Terminal
Permalink
Mo., 09.12.2024       AngioDynamics
US03475V1017

AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced it received U.S. Food and Drug Administration (FDA) 510(k) clearance for the NanoKnife System fo...
weiterlesen
AngioDynamics
Research & Analysen Termsheet Terminal
Permalink
Mi., 23.10.2024       AngioDynamics
US03475V1017

AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced the launch of an international multi-center prospective registry study to assess the long term e...
weiterlesen
AngioDynamics
Research & Analysen Termsheet Terminal
Permalink
Mo., 21.10.2024       AngioDynamics
US03475V1017

AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced that IRE has received CPT® Category I codes for the treatment of lesions in the prostate and liv...
weiterlesen
AngioDynamics
Research & Analysen Termsheet Terminal
Permalink
Do., 03.10.2024       AngioDynamics
US03475V1017

AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the first quarter of fiscal year 2025, which ended August 31, 2024. ...
weiterlesen
AngioDynamics
Research & Analysen Termsheet Terminal
Permalink
Do., 19.09.2024       AngioDynamics
US03475V1017

AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced the launch of the Prospective, Multicenter, Multi-national, Single Arm Trial Evaluating the Effi...
weiterlesen
AngioDynamics
Research & Analysen Termsheet Terminal
Permalink
Do., 19.09.2024       AngioDynamics
US03475V1017

AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it will report financial results for the first quarter of fiscal year 2025 before the marke...
weiterlesen
AngioDynamics
Research & Analysen Termsheet Terminal
Permalink
Di., 03.09.2024       AngioDynamics
US03475V1017

AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced European CE Mark approval of the Auryon Atherectomy System, an innovative technology for the tre...
weiterlesen
AngioDynamics
Research & Analysen Termsheet Terminal
Permalink
We are different
OPEN FINANCIAL
DATA & KNOWLEDGE HUB
We make the difference
Informationen zu Product Placements

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S